Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer acquires InnoPharma
Earlier, Pfizer agreed to make an upfront payment of $225m to InnoPharma and up to $135m of contingent milestone payments. InnoPharma has developed capabilities in complex injectable delivery
Earlier, Pfizer agreed to make an upfront payment of $225m to InnoPharma and up to $135m of contingent milestone payments. InnoPharma has developed capabilities in complex injectable delivery
Originated from the labs of David Baltimore, Nobel Laureate and President Emeritus, and Robert Andrews, Millikan Professor of Biology at Caltech, the technology uses the patient’s own hematopoietic
MM-398 is an investigational drug candidate designed to increase drug deposition and prolong cytotoxic effects, with the goal of improving its anti-cancer properties. Currently, Merrimack is preparing a
Under the deal, Sothema will be responsible for marketing and selling Zestra and its high viscosity water-based lubricant Zestra Glide in Middle East (Excluding Lebanon and Israel), North
More than 10,000 mosquitoes infected with bacteria that suppress dengue fever have been released by scientists at the Rio de Janeiro-based Fiocruz research institute to let them multiply
Currently, the company is enrolling cancer patients in a Phase Ib clinical trial and expects to complete the trial in the first quarter of 2015. In preclinical trials,
In October 2012, the FDA approved Minivelle for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause, also known as hot flashes. Minivelle includes bioidentical
The data submitted in the NDA includes a Japanese Phase III trial, which showed 100% SVR12 rates and patients who achieve SVR12 are cured of HCV infection. The
RDEB is the most severe form of the rare connective tissue disorder epidermolysis bullosa and it causes severe blistering and areas of missing skin that occurs when a
Olaptesed pegol is a PEGylated mirror-image (L-) oligonucleotide, which binds and neutralizes the chemokine CXCL12/SDF-1, preventing interaction with its receptors CXCR4 & CXCR7. The company develops a new